Celltrion achieved its highest-ever quarterly performance in the second quarter of 2025, fueled by robust sales of high-margin new products.
On July 21, Celltrion announced provisional consolidated results for Q2 2025, with sales of KRW 961.5 billion and operating profit of KRW 242.5 billion. Compared to the same period last year, sales rose by 9.9% while operating profit surged by 234.5%, setting a new record for second-quarter performance. The operating profit margin also improved to the 25% range.
This strong performance was driven by steady sales of existing products in global markets and a notable expansion in sales of new high-margin products. In particular, significant growth in products such as Remsima SC (sold in the U.S. as Zymfentra, for autoimmune diseases), Yuflyma (autoimmune diseases), Vegzelma (oncology), and Steqima (autoimmune diseases) greatly contributed to the increase in both sales and profitability. The proportion of sales from new high-margin products jumped to 53%, compared to 30% in the same quarter last year.
This momentum is expected to continue through the second half of the year. Celltrion is preparing to sequentially launch four new products globally, including Omriclo (for urticaria), Aptosma (autoimmune diseases), Idenzelt (ophthalmology), and Stoboclo-Ocenbelt (bone disorders). The company anticipates an even steeper growth trajectory compared to the first half of the year.
Profitability is also steadily improving thanks to ongoing cost-optimization efforts. Following the merger with Celltrion Healthcare, the cost of goods sold (COGS) ratio, which had temporarily risen, is rapidly decreasing due to the depletion of high-cost pre-merger inventory, increased operational efficiency at the third manufacturing plant, reduced outsourcing of APIs, and the completion of amortization for legacy product development costs. In Q2 2025, the COGS ratio stood at approximately 43%, down roughly 15 percentage points from 58% in the same period last year. Compared to the previous quarter alone, the company improved its COGS ratio by 4 percentage points, significantly expanding its profit margin.
A Celltrion spokesperson stated, “With the rollout of high-margin new products and the anticipated expansion in key global markets such as Europe and the U.S., we plan to continue company-wide efforts to drive growth throughout the second half of the year.”
